Cargando…

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

PURPOSE: Some patients with histologically confirmed primary mCRC and mutated RAS reported undetectable RAS mutant clones in plasma after receiving anti-VEGF treatment. The aim was to prospectively assess it with its potential therapeutic implications. METHODS: RAS mutant genes in solid biopsy (befo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernández Montes, A., Élez, E., Vivancos, A., Martínez, N., González, P., Covela, M., de la Cámara, J., Cousillas, A., Méndez, J. C., Graña, B., Aranda, E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Brief Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107427/ https://www.ncbi.nlm.nih.gov/pubmed/34997474 http://dx.doi.org/10.1007/s12094-021-02767-7

Ejemplares similares

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
por: Raimondi, Cristina, et al.
Publicado: (2019)

Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer
por: Bouchahda, Mohamed, et al.
Publicado: (2020)

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancer
por: Elez, Elena, et al.
Publicado: (2019)

Controversies in the treatment of RAS wild-type metastatic colorectal cancer
por: Vera, R., et al.
Publicado: (2020)

Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer.
por: Kopreski, M. S., et al.
Publicado: (1997)

Detection of Mutant RAS Subpopulations in Colorectal Cancer Patients
por: Banda, Malathi
Publicado: (2015)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
por: Veluchamy, John Pradeep, et al.
Publicado: (2016)

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
por: Grasselli, J, et al.
Publicado: (2017)

K-RAS Mutant Gene Found in Pancreatic Juice Activated Chromatin From Peri-ampullary Adenocarcinomas
por: Reza, Joseph, et al.
Publicado: (2019)

Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS‐mutant metastatic colorectal cancer
por: Huang, Weizhen, et al.
Publicado: (2022)

The effects of mutant Ras proteins on the cell signalome
por: Takács, Tamás, et al.
Publicado: (2020)

Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS
por: Ilter, Metehan, et al.
Publicado: (2022)

Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
por: Scharpf, Robert B., et al.
Publicado: (2022)

Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients
por: Nicolazzo, Chiara, et al.
Publicado: (2020)

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth
por: Shin, Seung-Min, et al.
Publicado: (2020)

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
por: Verissimo, Carla S, et al.
Publicado: (2016)

Selective and noncovalent targeting of RAS mutants for inhibition and degradation
por: Teng, Kai Wen, et al.
Publicado: (2021)

Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation
por: Ferguson, Robert, et al.
Publicado: (2023)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
por: McFall, Thomas, et al.
Publicado: (2022)

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
por: Ikoma, Tatsuki, et al.
Publicado: (2021)

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
por: Sorokin, Alexey V., et al.
Publicado: (2022)

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
por: Nichols, Robert J., et al.
Publicado: (2018)

Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
por: Jin, Hua, et al.
Publicado: (2019)

Clinicopathological Profiles Associated with Discordant RAS Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer
por: Brozos-Vázquez, Elena, et al.
Publicado: (2023)

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
por: García-Foncillas, Jesús, et al.
Publicado: (2018)

Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)
por: Sunakawa, Y., et al.
Publicado: (2022)

Comparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers
por: Kleiman, Laura B., et al.
Publicado: (2013)

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
por: Yang, Hang, et al.
Publicado: (2022)

Injury prevents Ras mutant cell expansion in mosaic skin
por: Gallini, Sara, et al.
Publicado: (2023)

Strategies to tackle RAS-mutated metastatic colorectal cancer
por: Patelli, G., et al.
Publicado: (2021)

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway
por: Gillies, Taryn E, et al.
Publicado: (2020)

Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer
por: Lee, Jennifer J., et al.
Publicado: (2021)

RAS testing in metastatic colorectal cancer: advances in Europe
por: Van Krieken, J Han JM, et al.
Publicado: (2015)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib
por: Booth, Laurence, et al.
Publicado: (2017)

Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials
por: Stahler, Arndt, et al.
Publicado: (2020)

An unexpected new role of mutant Ras: perturbation of human embryonic development
por: Kratz, Christian P., et al.
Publicado: (2007)

Interactions Between Wildtype and Mutant Ras Genes in Lung and Skin Carcinogenesis
por: To, Minh D., et al.
Publicado: (2012)

Cytotoxicity of Simvastatin to Pancreatic Adenocarcinoma Cells Containing Mutant ras Gene
por: Ura, Hitoshi, et al.
Publicado: (1994)

5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma
por: Nastasă, Cristina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6hrhkui439cmgs0f2131evjefq